Trending...
- Governor Gavin Newsom signs SB 27, strengthening California's CARE Act and expanding access to behavioral health services
- Cent Capital Launches FinPedia, a Free Financial Literacy Resource for Personal Finance and Investing
- Mullins McLeod Surges Into SC Governor's Race with $1.4 Million Raised in First Quarter; Most from His Own Commitment, Not Political Pockets
SAN DIEGO--(BUSINESS WIRE)--Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for immuno-fibrotic diseases and oncology, today announced the initiation of dosing in a Phase 1 study of LASN01, a novel interleukin-11 (IL-11) receptor-blocking antibody. The Phase 1 single and multiple ascending dose study will evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of LASN01 in healthy volunteers.
"The initiation of this trial is an important milestone for Lassen and continues our progress towards developing a new treatment option for patients with excessive fibrosis," said Puneet Arora, MD, Chief Medical Officer of Lassen. "IL-11 plays a critical role in the initiation and maintenance of chronic fibrotic responses and as a result, blocking this pathway represents a promising approach for multiple diseases characterized by unchecked fibrosis. We believe LASN01 has best-in-class potential to block IL-11 signaling and reduce fibrosis."
The initiation of this Phase 1 trial and the LASN01 clinical program is based in part on pre-clinical data reported at the American Thoracic Society (ATS) Annual Meeting 2022. The data presented at ATS demonstrated potent blockade of IL-11-stimulated signaling by LASN01 and inhibition of TGF-β-stimulated collagen expression by patient-derived idiopathic pulmonary fibrosis (IPF) fibroblasts. In ex vivo assays using human lung tissue, LASN01 inhibited TGF-β-stimulated production of the fibrotic markers procollagen type I and tissue inhibitor of metallopeptidase 1 (TIMP1), and reduced collagen neo-epitope release from slices of diseased IPF lung tissue. Inhibition of IL-11 signaling also showed a significant anti-fibrotic effect in the lung and skin in animal models of fibrosis.
More on The Californer
More information on the Phase 1 study (NCT05331300) is available at clinicaltrials.gov.
About Lassen Therapeutics
Lassen Therapeutics develops breakthrough antibodies as potential treatments for immuno-fibrotic diseases and oncology. The company's lead candidate is LASN01, a best-in-class monoclonal antibody targeting IL-11 receptor (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis and blocking its activity has the potential to be safer than, and additive to, other anti-fibrotic therapeutic approaches. IL-11 is also an important effector of tumor microenvironment organization, playing a key role as a mediator between cancer and stromal cells. The company is also developing a novel immuno-oncology therapeutic targeting interleukin-18 binding protein (IL-18BP), a checkpoint on IL-18 activity. Our antibodies inhibit the checkpoint activity of IL-18BP to allow IL-18 to stimulate multiple immune cell populations including enhancement of NK and T cell mediated immune responses to tumors. The program is at lead optimization stage.
More on The Californer
For more information, please visit www.lassentherapeutics.com.
Contacts
Media:
Christine Quern
CBQ Communications
cq@christinequern.com
617.650.8497
"The initiation of this trial is an important milestone for Lassen and continues our progress towards developing a new treatment option for patients with excessive fibrosis," said Puneet Arora, MD, Chief Medical Officer of Lassen. "IL-11 plays a critical role in the initiation and maintenance of chronic fibrotic responses and as a result, blocking this pathway represents a promising approach for multiple diseases characterized by unchecked fibrosis. We believe LASN01 has best-in-class potential to block IL-11 signaling and reduce fibrosis."
The initiation of this Phase 1 trial and the LASN01 clinical program is based in part on pre-clinical data reported at the American Thoracic Society (ATS) Annual Meeting 2022. The data presented at ATS demonstrated potent blockade of IL-11-stimulated signaling by LASN01 and inhibition of TGF-β-stimulated collagen expression by patient-derived idiopathic pulmonary fibrosis (IPF) fibroblasts. In ex vivo assays using human lung tissue, LASN01 inhibited TGF-β-stimulated production of the fibrotic markers procollagen type I and tissue inhibitor of metallopeptidase 1 (TIMP1), and reduced collagen neo-epitope release from slices of diseased IPF lung tissue. Inhibition of IL-11 signaling also showed a significant anti-fibrotic effect in the lung and skin in animal models of fibrosis.
More on The Californer
- LIB Industry Expands Full-Series Salt Spray Corrosion Test Chambers to Meet Global Testing Standards
- The Easy Way to Collect Every Wedding Photo from Your Guests - No App Needed
- Rick Roco Ignites San Francisco's Pop Surrealism Scene
- Official City of Long Beach Statement Regarding Cease and Desist Notices for Unpermitted Event on October 11, 2025
- REPRESENTATION REVOLUTION: FLM TV Network Launches as America's First Truly Diverse Broadcast Network
More information on the Phase 1 study (NCT05331300) is available at clinicaltrials.gov.
About Lassen Therapeutics
Lassen Therapeutics develops breakthrough antibodies as potential treatments for immuno-fibrotic diseases and oncology. The company's lead candidate is LASN01, a best-in-class monoclonal antibody targeting IL-11 receptor (IL-11R). IL-11, a member of the IL-6 family of cytokines, is a central mediator of fibrosis and blocking its activity has the potential to be safer than, and additive to, other anti-fibrotic therapeutic approaches. IL-11 is also an important effector of tumor microenvironment organization, playing a key role as a mediator between cancer and stromal cells. The company is also developing a novel immuno-oncology therapeutic targeting interleukin-18 binding protein (IL-18BP), a checkpoint on IL-18 activity. Our antibodies inhibit the checkpoint activity of IL-18BP to allow IL-18 to stimulate multiple immune cell populations including enhancement of NK and T cell mediated immune responses to tumors. The program is at lead optimization stage.
More on The Californer
- Hunger Action Los Angeles to Host 2025 Fundraising Gala on World Food Day at Guelaguetza Restaurant
- OhMyPretty Burmese Curly Bundles Redefine Long-Lasting, Chic, Versatile Curls
- New Book Call all Jews to Accept Jesus as the Messiah
- Flux AI Launches CRAISEE — The World's First All-in-One Generative AI Platform
- Governor Newsom pre-deploys additional storm safety resources to Southern California ahead of extreme weather
For more information, please visit www.lassentherapeutics.com.
Contacts
Media:
Christine Quern
CBQ Communications
cq@christinequern.com
617.650.8497
Filed Under: Business
0 Comments
Latest on The Californer
- Florida International University: "Psychiatry: An Industry of Death" Traveling Exhibit Educates Students on Mental Health Abuse
- Governor Newsom signs bills to further strengthen California's leadership in protecting children online
- SAEN Ranked Among the Top 5 Bay Area Artists of 2025 — Just Behind Easton Cain
- CCHR: VA's Psychiatric Treatments Betray Veterans, Fuel Suicide and Death
- Integris Composites Named Armor Partner for U.S. Army's XM30 Combat Vehicle
- Limited Time: Get $50 Off Water Heater Replacement or Installation from Curoso Plumbing
- Viewing Figures: Soap Opera Insights and Viewership
- Destination: Scientology, Del Valle Celebrates the Cultural Heritage of Mexico
- Jaipur Countryside, 4-Star Comfort: $199 for Two— All-Inclusive with Meals + Transfers at Heritage Hotel Savista
- The Underdog Rises: The First Lady Olivia and Tanasha Donna
- California: Governor Newsom signs bill to protect parents' rights and children
- Probate Shepherd® Announces a New Member Probate Attorney in Fort Worth, TX
- Phinge Announces "Test the Waters" Campaign for Potential Regulation A+ Offering: Home of Netverse Verified AI & Patented App-less Technology Platform
- Why Jobseekers Should Invest in a Professional Resume Writer
- Voices for Humanity Leads Resurgence of Moral Values in Hungary with Antónia and Ferenc Novák
- Richline Transportation Elevates San Diego Airport Transfers with Luxury Black Car Service
- RJ Grimshaw Launches "The AI EDGE" A Practical Guide Where Leadership Meets Innovation
- WECS TV Show San Francisco ~ Dallas Spotlights Sherri Young, AASC Executive Director
- California: Governor Newsom statement on the passing of Diane Keaton
- California: Governor Newsom issues legislative update 10.11.25